Cite

    Colombel, J. et al. (2017). Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Alimentary pharmacology & therapeutics. 45 (1), pp. 50-62. [Online].